Axios Re:Cap

Biotech investor Bob Nelsen on AstraZeneca and his plan to revolutionize pharma

AstraZeneca and the University of Oxford today reported promising efficacy data for their COVID-19 vaccine, which has less stringent storage requirements than the Pfizer and Moderna vaccines and which may be distributed earlier in developing countries. Dan digs into the state of vaccine and therapeutics manufacturing with Bob Nelsen, a successful biotech investor who today launched Resilience, a giant new pharma production platform that he believes will prepare America for its next major health challenges.
Plus, Axios health care editor Sam Baker joins to discuss AstraZeneca’s interim analysis.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Each weekday afternoon, Axios unpacks the biggest story of the day and why it matters. We'll take you inside the accelerating forces, technologies and trends that are remaking your world and work. About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app. 

Axios Re:Cap is on hiatus until October 2021.